Medical Therapies of DHF and the Concept of "Diuretic Resistance"
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Consultant Fee/Honoraria/Speaker's Bureau - Sequana Medical AV; Owkin; Applied Therapeutics Inc; Relypsa Inc; preCARDIA, Inc; Genomics plc; Cardiol Therapeutics Inc; American Board of Internal Medicine; Springer Nature; Boston Scientific Corporation; WhiteSwell; Renovacor Inc; Zehna Therapeutics LLC; CardiaTec Biosciences
- Grant Support/Research Contract - Alnylam Pharmaceuticals; Pfizer Inc / Array Biopharma; 3Live, Inc; SalubrisBio; Bristol-Myers Squibb; Pfizer Inc; BioCardia Inc; Cordio